LSD: Part II, The Modern Era

***Disclaimer: this podcast is intended for informational purposes only on the safety and efficacy data of the substances discussed. As healthcare professionals, we do not advocate for or against the use of substances which are considered illicit by the United States Drug Enforcement Administration*** References: Bonson KR, et al. Chronic administration of serotonergic anti-depressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology. 1996; 14(6) Gasser P, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. The Journal of Nervous and Mental Disease. 2014; 202(7): 513-520 Lopez-Gimenez JF, Gonzalez-Maeso J. Hallucinogens and Serotonin 5HT2A Receptor Mediated Signaling Pathways. Current Topics in Behavioral Neuroscience. 2018; 36: 45-73 Liechti ME. Modern Clinical Research on LSD. Neuropsychopharmacology. 2017; 42: 2114-2127. Murphy RJ, et al. MDLSD: study protocol for a randomised, double-masked, placebo-controlled trial of repeated microdoses of LSD in healthy volunteers. Trials. 2021; 22. https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05243-3 Murphy RJ, et al. Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled Trial. Biological Psychiatry. 28 March 2023. https://www.biologicalpsychiatryjournal.com/article/S0006-3223(23)01164-2/fulltext#gr2 Passie T, et al. The pharmacology of lysergic acid diethylamide: a review. CNS Neuroscience and Therapeutics. 11 Nov 2018. https://onlinelibrary.wiley.com/doi/10.1111/j.1755-5949.2008.00059.x Get full access to Neural Pharm at neuralpharm.substack.com/subscribe